Waldencast (WALD) announced that the U.S. FDA has approved Obagi saypha MagIQ injectable hyaluronic acid gel, the first product in the Obagi saypha collection under the Obagi Medical brand. This approval marks Waldencast’s entry into the U.S. HA dermal filler market through Obagi Medical and reinforces the company’s ambition to become a multi-product innovator in aesthetics, doubling Obagi Medical’s total addressable market to approximately $4.2B by 2029.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Reports Strategic Growth and New Acquisitions
- Waldencast’s Strategic Positioning and Growth Potential: A Buy Rating Amidst Strategic Review and Financial Restructuring
- Waldencast price target lowered to $3 from $4 at Telsey Advisory
- Waldencast price target lowered to $2 from $2.40 at TD Cowen
- Waldencast Reports Strong H1 2025 Growth and Strategic Initiatives